Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell LymphomaJason R. Westin, Anna Sureda, Michael Dickinson et al.|Clinical Cancer Research|2023Cited by 51